Clinical Trial Update: Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating safety and immunogenicity of HIV vaccine 732461 in healthy HIV-seronegative volunteers completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• HIV Infections

Drugs mentioned

• HIV vaccine 732461

Snippet

Sponsor: GlaxoSmithKline | Conditions: AIDS, HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-10-01